source
- Trump unveils pricing agreements with midsize biotech firms; Novartis halts CAR-T trial after patient deathsThe White House announced that President Trump has struck new pricing agreements with a group of midsize biotechnology companies, aiming to adjust drug costs. Novartis disclosed that it is pausing…
- Mid-size biotechs join White House Medicaid pricing program, gain tariff reliefNine mid-size drugmakers announced they will take part in the White House’s GENEROUS Medicaid pricing model, which ties U.S. Medicaid payments to the lowest prices paid abroad. In return, the comp…